Online Program Home
My Program

Abstract Details

Activity Number: 37 - Statistical Issues Specific the Therapeutic Areas - 1
Type: Contributed
Date/Time: Sunday, July 29, 2018 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract #330378 Presentation
Title: Meta-Analysis for the Adjuvant Treatment in Renal Cell Carcinoma
Author(s): Weichao Bao*
Companies: Novartis Pharmaceuticals Corporation
Keywords: Meta-analysis; Bayesian

To evaluate the class effect of VEGF-TKI as adjuvant therapy in renal cell carcinoma (RCC), a meta-analysis was conducted based on summary level data from three phase III studies: ASSURE (Haas et al., 2016), S-TRAC (Ravaud et al., 2016) and PROTECT (Motzer et al., 2017). All three studies are placebo controlled randomized phase III studies in patients with intermediate or high risk of relapse to RCC, and sorafenib, sunitinib and pazopanib were studied respectively. The primary endpoint for all three studies is disease free survival (DFS).

The VEGF-TKI effect vs placebo was estimated via hazard ratio and 95% confidence/credible intervals using both frequentist and Bayesian approaches in the meta-analysis.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2018 program